Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Vera Therapeutics (Nasdaq: VERA) announced inducement awards granted April 8, 2026 to 89 new employees under its 2024 Inducement Plan. The Compensation Committee approved non-qualified stock options for 258,200 shares and RSUs underlying 131,925 shares.

Options carry an exercise price of $40.33 per share (closing price on April 8, 2026) and vest over four years; RSUs vest annually over four years beginning May 20, 2026.

News Market Reaction – VERA

-2.95%

49 alerts

-2.95% News Effect

+10.1% Peak in 3 hr 46 min

-$102M Valuation Impact

$3.35B Market Cap

1.2x Rel. Volume

On the day this news was published, VERA declined 2.95%, reflecting a moderate negative market reaction. Argus tracked a peak move of +10.1% during that session. Our momentum scanner triggered 49 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $102M from the company's valuation, bringing the market cap to $3.35B at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details routine inducement equity awards—258,200 stock options and 131,925 RSUs—to...

Analysis

This announcement details routine inducement equity awards—258,200 stock options and 131,925 RSUs—to 89 new employees at an exercise price of $40.33, vesting over four years. It follows earlier inducement grants and leadership changes, continuing Vera’s use of equity for hiring and retention under the 2024 Inducement Plan. Investors may track how cumulative awards affect total dilution alongside existing catalysts such as the upcoming July 7, 2026 PDUFA date.

Key Figures

Stock options granted: 258,200 shares RSUs granted: 131,925 shares New employees: 89 employees +5 more

8 metrics

Stock options granted 258,200 shares Non-qualified options under 2024 Inducement Plan for new employees

RSUs granted 131,925 shares Restricted stock units for new employees under Inducement Plan

New employees 89 employees Recipients of inducement equity awards

Option exercise price $40.33 Closing price on April 8, 2026 for inducement options

Option vesting term 4 years 25% after one year, remainder monthly over 36 months

RSU vesting term 4 years 25% on each anniversary of May 20, 2026

Pre-news price change 1.49% 24h move before publication, price at $45.04

52-week range $18.53–$56.05 Price 143.07% above low and 19.64% below high

Historical Context

5 past events · Latest: Mar 27 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 27	Inducement grants	Neutral	-2.0%	Equity inducement awards for new Chief Legal Officer under 2024 Inducement Plan.
Mar 25	Executive appointment	Positive	+1.0%	Appointment of Chief Legal Officer to support regulatory and commercialization efforts.
Mar 06	Inducement grants	Neutral	-0.3%	Inducement equity awards to six new employees under the 2024 Inducement Plan.
Mar 05	Board appointment	Positive	-2.0%	New independent director added to support commercial and financial strategy.
Feb 26	Earnings and update	Positive	+1.6%	Full-year 2025 results with positive Phase 3 data and FDA priority review.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Routine governance and compensation news (board/management changes, inducement grants) has produced mixed short-term price reactions, while larger strategic and clinical/financial updates have tended to see modest positive alignment.

Recent Company History

Over the last few months, Vera reported full-year 2025 results with positive Phase 3 atacicept data, FDA priority review, and a July 7, 2026 PDUFA date, alongside financings totaling potential gross proceeds of $800 million and year-end cash of $714.6 million. Governance and leadership updates included new board and executive appointments plus multiple inducement equity grants under the 2024 Inducement Plan. Today’s broader employee inducement grants continue that pattern of using equity for hiring and retention rather than signaling a new strategic shift.

Key Terms

non-qualified stock options, restricted stock units, nasdaq listing rule 5635(c)(4), class a common stock

4 terms

non-qualified stock options financial

"granted inducement awards consisting of non-qualified stock options to purchase 258,200 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units financial

"and restricted stock units (RSUs) underlying 131,925 shares of Class A common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

class a common stock financial

"options to purchase 258,200 shares of Class A common stock and restricted stock units"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on April 8, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 258,200 shares of Class A common stock and restricted stock units (RSUs) underlying 131,925 shares of Class A common stock to eighty-nine (89) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option granted on April 8, 2026 has an exercise price per share equal to $40.33, Vera Therapeutics’ closing trading price on April 8, 2026. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of May 20, 2026, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Vera Therapeutics
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also evaluating development of MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109 and MAU868. For more information, please visit www.veratx.com.

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com

FAQ

What inducement grants did Vera Therapeutics (VERA) approve on April 8, 2026?

They approved non-qualified stock options for 258,200 shares and RSUs for 131,925 shares. According to the company, the Compensation Committee granted these awards to 89 new employees under the 2024 Inducement Plan as inducements to employment.

What is the exercise price and vesting schedule for VERA stock options granted April 8, 2026?

The exercise price is $40.33 per share, equal to the April 8, 2026 closing price. According to the company, options vest over four years: 25% at the first anniversary, then monthly over the next 36 months, subject to continued service.

When do the RSUs granted by Vera Therapeutics (VERA) begin vesting and over what period?

RSUs vest over four years, with 25% of shares vesting on each anniversary beginning May 20, 2026. According to the company, vesting is conditioned on the new employee's continued service through each applicable vesting date.

How many employees received inducement awards from Vera Therapeutics (VERA) and under what plan?

Eighty-nine new employees received the inducement awards under the Vera Therapeutics 2024 Inducement Plan. According to the company, the grants were approved by the Compensation Committee as material inducements to employment.

Do the VERA inducement awards have any conditions or agreement terms attached?

Yes, the awards are subject to the Inducement Plan terms and applicable award agreements. According to the company, each grant is governed by the plan and an award agreement outlining vesting, service conditions, and other terms.